CSL Behring, Leader in Rare Diseases, Hosts a Symposium on CIDP, Presents 7 Poster Sessions Featuring PATH Study Data at the 15th International Congress on Neuromuscular Diseases

- CSL Behring hosts symposium featuring patient perspective on subcutaneous immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) treatment

- CSL Behring offers a portfolio of immunoglobulin therapies to address the unique needs of CIDP patients – Hizentra®, the first and only subcutaneous immunoglobulin option for CIDP patients and Privigen®, approved for treating CIDP since 2013

VIENNA, Austria – 5 July 2018 – Global biotherapeutics leader CSL Behring today announced that it will participate in the 15th International Congress on Neuromuscular Diseases (ICNMD) in Vienna, Austria.  A symposium “Subcutaneous Immunoglobulin in CIDP:  Getting Under the Skin” will feature both a clinical review and a patient’s perspective on intravenous versus subcutaneous administration.   In addition, CSL Behring will support seven scientific poster presentations with a focus on data from the PATH (Polyneuropathy and Treatment with Hizentra) study, the largest ever CIDP trial.  The Company will also host an exhibit (#12) where visitors will have an opportunity to partner with CSL Behring as they donate to the GBS|CIDP Foundation International for every badge scanned at their booth.

“Our focus here at ICNMD is to present data that will ultimately advance patient care by giving neurology healthcare professionals new insights on subcutaneous immunoglobulin treatment for CIDP,” said Gabriela Espinoza, Director, Global Medical Affairs, Immunoglobulins, CSL Behring.  “CSL Behring is proud of its long history in delivering on its promise to develop therapies that treat rare and serious conditions and pleased to be here connecting with the neuromuscular community.”

During Saturday’s Symposium, “Subcutaneous Immunoglobulin in CIDP:  Getting Under the Skin” (7 July 12:15-13:45, Park 1) Dr. Vera Bril will chair the discussion around the use of subcutaneous Immunoglobulin in CIDP.  Hans Katzberg will discuss the PATH study and will be joined by Dorothea Grosse-Kreul who will provide a nurse’s perspective on subcutaneous administration, along with a CIDP patient who will share his experiences with intravenous and subcutaneous Immunoglobulin therapy. 

Seven posters summarizing research supported by CSL Behring will be presented In Congress 1-2 on Sunday, 8 July from 17:15 to 18:30 including:

  • Electrophysiological Testing in Patients With Chronic Inflammatory Demyelinating Polyneuropathy Treated With Subcutaneous Immunoglobulin: The PATH Study (Bril, Van Schaik, et al.)
  • Quality of Life in a Clinical Study of Maintenance Treatment of CIDP With lgPro20: The PATH study (Hartung H-P et al)
  • Efficacy and Safety of Intravenous Immunoglobulin lgPro10 in CIDP: Combined Analysis of the PRIMA and PATH Studies (Merkies I et al)
  • Feasibility of Switching from Intravenous to Subcutaneous Ig Therapy in CIDP:PATH Trial Results Versus Clinical Experience (Cocito D et al presented byHartung H-P)
  • Restabilization Treatment After IVIG Withdrawal in Chronic Inflammatory Demyelinating Polyneuropathy:The PATH Study Results (Mielke O et al presented by Merkies I)
  • Axonal Function Predicts Response to Subcutaneous Immunoglobulin in CIDP:The PATH Study (Bril V et al)
  • Benefit-Risk Profile of Intravenous Immunoglobulin (IVIG) and Subcutaneous Immunoglobulin (SCIG) in CIDP: The PATH Study (Shebl O et al)

About CIDP

In CIDP, a rare autoimmune disorder that affects the peripheral nerves (those outside the brain and spinal cord), the myelin sheath, the protective covering of the nerves, is damaged. This may result in numbness or tingling, muscle weakness, fatigue, and other symptoms. CIDP effects can worsen over time, leading to significant activity limitations and a decreased quality of life. CIDP can occur at any age and is more common in men than in women. Approximately 30 percent of CIDP patients will progress to wheelchair dependence if not treated. It is estimated that the global incidence of CIDP is 0.5 to 1.6 patients per 100,000 individuals each year, with a prevalence of 1.0 to 8.9 per 100,000 people.

About Hizentra®

Hizentra (human normal immunoglobulin, SCIg), the first 20 percent subcutaneous immunoglobulin developed for subcutaneous use, is registered in over 51 countries and approved to treat CIDP and certain immune deficiencies. Hizentra, the world's most prescribed subcutaneous immunoglobulin, has a proven track record of safety, efficacy, and tolerability and has over 4.8 million exposures worldwide since 2010.

About Privigen®

Privigen (human normal immunoglobulin, IVIg), is the first and only 10 percent, ready to use, room-temperature stored, liquid IVIg stabilized with proline. A naturally occurring amino acid, proline has been shown to reduce IgG aggregation and dimer formation. Privigen has been approved to treat CIDP since 2013. Privigen is also approved for treating certain immune deficiencies, primary immune thrombocytopenic purpura (ITP), Guillain-Barré syndrome, and Kawasaki disease. It is approved in 80 countries around the world for treating these and other rare diseases.

About CSL Behring

CSL Behring is a global biotherapeutics leader driven by its promise to save lives. Focused on serving patients’ needs by using the latest technologies, we develop and deliver innovative therapies that are used to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, inherited respiratory disease, and neurological disorders. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic disease of the newborn.

CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (ASX:CSL), headquartered in Melbourne, Australia, employs nearly 20,000 people, and delivers its life-saving therapies to people in more than 60 countries. For more information visit www.cslbehring.com and follow us on www.Twitter.com/CSLBehring.

# # #

Media Contact
Jennifer Purdue
Office: +1 610 878 4802
Mobile: +1 610 306 9355
Email:
jennifer.purdue@cslbehring.com